Venetoclax (Venclexta)
Abstract
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Venetoclax (Venclexta), 10 mg, 50 mg, and 100 mg oral tablets. Indication: In combination with ibrutinib, for the treatment of adult patients with relapsed or refractory MCL.
Fields of Study & Subjects
Chronic Lymphocytic Leukemia Research
Health Systems
Economic Evaluations
Quality of Life
Lymphoma Diagnosis and Treatment
Publication details
- Journal / source
- Canadian Journal of Health Technologies
- Volume
- 6
- Issue
- 3
- Publication date
- 11 March 2026
- Language
- EN